Keith T. Flaherty has been elected as the AACR President-Elect for 2025-2026
AACR shared a post on LinkedIn:
“Keith T. Flaherty, MD, a Fellow of the AACR Academy, has been elected as the AACR President-Elect for 2025-2026.
Dr. Flaherty’s term as President-Elect will begin at the AACR Annual Business Meeting of Members on April 28, during the AACR Annual Meeting 2025 in Chicago. He will assume the Presidency during the AACR Annual Meeting 2026 in San Diego.
Flaherty’s career has focused on understanding the molecular and clinical consequences of inhibiting oncogenic pathways in melanoma while establishing therapeutic approaches and constructing rational combinatorial therapies for the treatment of this disease.
He has pioneered the development of targeted therapies matched to the genetic characteristics of a patient’s tumor and led early clinical trials testing vemurafenib and other therapeutic agents for the treatment of melanoma.
Through his work, Flaherty has translated discoveries about the BRAF V600E somatic mutation in cancer into effective therapies, including the FDA-approved combination targeted therapy regimens for melanoma.”
You may also be interested:
Keith T. Flaherty – Candidate for President Elect of AACR
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023